Research Report

Author

李曉然小姐(Margaret Li)
分析師

本科主修市場行銷和英語,並於香港浸會大學獲得經濟學碩士學位。現為輝立証券持牌分析師,主要負責能源和公用事業等板塊的研究。曾在大型銀行、券商和資產管理公司工作,對於期貨和大宗商品衍生品領域擁有銷售、研究分析和市場推廣等工作經驗。

Margaret, a holder of a Bachelor`s degree in Marketing and English and a Master`s degree in Applied Economics from Hong Kong Baptist University, is currently employed as a licensed analyst at Phillip Securities. She specializes in conducting research focusing on the energy and utilities sectors. Prior to her current position, Margaret gained valuable work experience in a large bank, securities firm, and asset management companies. Her expertise lies in sales, research analysis, and marketing within the fields of futures and commodities derivatives.


Phone: 22776535  
Email Enquiry For Research Report and Business enquiry

Proya Cosmetics (603605.CH) - Revenue exceeded 10 billion for the first time, and valuation remains attractive

Wednesday, August 13, 2025 Views258
Proya Cosmetics
Recommendation on  13 August 2025
Recommendation Buy
Price on Recommendation Date $82.580
Target Price $114.000

Overview

As a leading domestic cosmetics company, Proya Cosmetics primarily engages in R&D, production, and sales of cosmetic products. Its offerings span skincare, makeup, cleansing & personal care, and more. The company owns brands such as Proya, Hapsode, Timage, Off&Relax, CORRECTORS, INSBAHA, UZERO and Anya.

Performance review

In 2024, the company achieved revenue of RMB 10.78 billion with a year-on-year (YoY) increase of 21.04%, surpassing the RMB 10 billion mark for the first time, primarily driven by growth in online channel revenue. Operating costs were RMB 3.08 billion (YoY +15.18%). Selling expenses reached RMB 5.16 billion (YoY +29.93%), mainly due to increased brand promotion and marketing expenses. R&D expenses were RMB 210 million (YoY +21.21%), with an R&D expense ratio of 1.95%, remaining largely flat YoY. Net profit attributable to shareholders was RMB 1.55 billion (YoY +30%). Net cash flow from operating activities was RMB 1.12 billion (YoY -24.6%), primarily due to increased payments for goods, marketing expenses, taxes, and employee compensation. Basic earnings per share (EPS) were RMB 3.93 (YoY +30.56%).

In Q1 2025, the company recorded revenue of RMB 2.36 billion (YoY +8.13%). Net profit attributable to shareholders was RMB 390 million (YoY +28.87%). Net cash flow from operating activities was RMB 675 million (YoY +56.78%). Basic EPS was RMB 0.99 (YoY +30.26%). The Q1 revenue growth rate was notably slower than the full-year 2024 growth. We attribute this primarily to Q1 not being the peak season for cosmetics consumption, which is typically concentrated in the summer months (June-August) and during major year-end promotional events (October-December).

Outstanding 618 Performance: Topping Platform Brand Rankings

According to National Bureau of Statistics data, China's total retail sales of consumer goods in H1 2025 reached RMB 2,4545.8 billion (YoY +5%). Retail sales of cosmetics amounted to RMB 229.1 billion (YoY +2.9%), exceeding the H1 2024 growth rate, demonstrating the industry's resilience and sustained upward trend. Data from Qingyan Intelligence shows that the total GMV across four major platforms (Taobao/Tmall, Douyin, JD.com, Kuaishou) during the 2025 618 shopping festival period (May 13 - June 18) reached RMB 65.91 billion with a YoY increase of over 10%. This year, Tmall simplified its promotions, replacing complex tiered discounts with a straightforward ൗ% Official Instant Discount," supplemented by category and general consumption coupons. This approach maintained competitive pricing while avoiding excessive "cutthroat price competition."

The company delivered an outstanding 618 performance across its brands:

Proya: Topped multiple platform rankings, including Tmall Beauty (Full Period), Douyin 618 Good Things Festival (Skincare), JD.com Domestic Beauty Brand, and Pinduoduo Domestic Beauty Brand.

Timage: Experienced strong growth across three major platforms, ranking first in Tmall Color Cosmetics, second in JD.com Domestic Color Cosmetics, and fifth in Douyin Domestic Color Cosmetics, with GMV growth 10%+, 20%+, and 30% YoY respectively. Key products like the Little Round Tube Foundation, Primer, Trio Contour Palette, and Trio Concealer topped their categories.

Off&Relax: Achieved over 148%+ YoY growth across all channels, hitting new record high. Tmall dual-store GMV grew over 110%+ YoY, Douyin dual-store GMV surged over 200%+ YoY, and JD.com dual-store GMV jumped over 270%+ YoY. Star products like the OR Anti-Hair Loss Serum, Volumizing Shampoo, and Hair Oil performed exceptionally well.

Hapsode: GMV grew 23.5% YoY on Douyin, 69% on JD.com, and 23% on Pinduoduo.

INSBAHA: Achieved over 106%+ YoY GMV growth across all platforms and is rapidly emerging as one of the company's fastest-growing new brands, poised to contribute significantly to future incremental growth.

Strategic Collaboration with Bota Bio: Exploring Synthetic Biology

In May 2025, Proya signed a strategic cooperation agreement with Bota Bio, marking its first partnership with a synthetic biology enterprise. The collaboration will focus on integrating synthetic biology and AI technologies for the innovative development and application of cosmetics and biomedical aesthetic materials. The partners aim to jointly build an innovation matrix for bio-based functional active ingredients, accelerating breakthroughs and enabling diverse applications in cosmetics and biomedical materials. This will provide consumers with more effective, green, and safe products. The collaboration is expected to enhance Proya's competitiveness in bio-based ingredient innovation, product technology barrier creation, and sustainability.

Strategic Partnership with Ant Group: AI Empowering Beauty

In May 2025, Proya entered a strategic partnership with Ant Group's Beijing Digital Mali Technology Co., Ltd. Beijing Digital Mali Technology will assist Proya in enhancing consumer experience through AI-powered cloud customer service, AI smart inspection, and full-chain user experience solutions. It will also leverage AI to boost Proya's competitiveness in enterprise digital operations, energy conservation, emission reduction, and green initiatives. This collaboration is a key step in Proya's digital transformation, aiming for short-term cost reduction and efficiency gains through AI customer service and smart quality inspection, better supporting operational stability during peak sales seasons.

Partnership with Top-Tier Hospital: Collaborative R&D on Mitochondrial Anti-Aging

In July 2025, the company signed an agreement with West China Hospital of Sichuan University focusing on "mitochondrial anti-aging" research. This aims to leverage cutting-edge medical research to empower cosmetic innovation, establishing a full-chain "industry-academia-research-medicine" collaborative model. Mitochondrial research is becoming a crucial frontier in tech-driven anti-aging. The partnership will integrate West China Hospital's advanced research resources to deeply investigate the intrinsic link between mitochondrial function and skin aging at the cellular level, identify key pathways and targets, accelerate R&D and screening of potent anti-aging actives, and lay a solid foundation for future product applications. However, mitochondrial anti-aging research involves complex biological mechanisms, and the path from basic research to marketable products is lengthy, carrying risks of delayed or unsuccessful technology translation.

Valuation and Investment Recommendation

The competitive landscape of the beauty industry is undergoing a reshuffle. Only brands with strong product competitiveness and adept platform resource utilization will thrive. Proya possesses robust product innovation and channel operation capabilities within the domestic beauty sector. Its consistent execution of the "hot product strategy" and continuous portfolio enrichment solidify its leadership position. We anticipate the company will gradually transition from high growth to a more stable phase, but double-digit revenue growth is still expected in the near term.

We forecast the company's operating revenue for 2025-2027 at RMB 12.39 billion, RMB 14.10 billion, and RMB 15.79 billion, respectively. EPS is projected at RMB 4.56, RMB 5.31, and RMB 6.02 for 2025-2027. This translates to P/E ratios of 18.11x, 15.54x, and 13.72x for 2025-2027. We assign a target price of RMB 114, representing 25x our projected 2025 P/E, and maintain a "Buy" rating.

Risk Factors

1) Downward macroeconomic situation;
2) Intensified industry competition;
3) Management changes;
4) New product promotion failing to meet expectations.

Financial Data

"Financial

Current Price as of: 11 Aug 2025
Source: PSHK Est.

Download PDF Version Here...

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
新闻稿
E-Check
Login
Investor Notes
Free Subscribe
Contact Us